Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
ACETYLSALICYLIC ACID
PHARMASCIENCE INC
B01AC06
ACETYLSALICYLIC ACID
81MG
TABLET (DELAYED-RELEASE)
ACETYLSALICYLIC ACID 81MG
ORAL
7/30/120/150/180/255/300/360/365/500/1000
OTC
SALICYLATES
Active ingredient group (AIG) number: 0101169013; AHFS:
CANCELLED POST MARKET
2017-10-21
PRODUCT MONOGRAPH ENTERIC COATED ASA DAILY LOW DOSE Acetylsalicylic Acid Delayed-release Tablets, USP 81 mg Analgesic, anti-inflammatory, antipyretic and Platelet aggregation inhibitor PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montreal, Quebec H4P 2T4 DATE OF REVISION: March 08, 2017 SUBMISSION CONTROL NUMBER: 199017 _ENTERIC COATED ASA DAILY LOW DOSE Product Monograph _ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ................................................................................9 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY ..........................................................................................12 SPECIAL HANDLING INSTRUCTIONS .......................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13 PART II : SCIENTIFIC INFORMATION ...............................................................................14 PHARMACEUTICAL INFORMATION ..........................................................................1 Đọc toàn bộ tài liệu